R R

What Is Pharmacovigilance?

Pharmacovigilance is the science and organized activity of detecting, assessing, understanding, and preventing adverse effects or other medicine-related problems. It covers safety monitoring throughout a product's life cycle, from clinical development through postmarketing use. The work examines known risks, possible new risks, medication errors, interactions, and patterns of harm. Its purpose is to support safer use and maintain an appropriate balance between a medicine's benefits and risks.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Pharmacovigilance?

Pharmacovigilance is the science and organized activity of detecting, assessing, understanding, and preventing adverse effects or other medicine-related problems. It covers safety monitoring throughout a product's life cycle, from clinical development through postmarketing use. The work examines known risks, possible new risks, medication errors, interactions, and patterns of harm. Its purpose is to support safer use and maintain an appropriate balance between a medicine's benefits and risks.

read more about pharmacovigilance ...

Copy this HTML:

Copy HTML Copied!

What Information Is Used in Pharmacovigilance?

Safety information comes from clinical trials, spontaneous adverse-event reports, medical literature, observational studies, registries, and healthcare databases. Reports can be submitted by patients, caregivers, clinicians, pharmacists, manufacturers, and other sources. Product-quality complaints, medication errors, pregnancy exposures, and lack of expected effect can also be relevant. A single report can be valuable, but larger patterns and supporting evidence are commonly needed to understand a risk.

How Are Safety Signals Identified and Assessed?

A safety signal is information suggesting a new possible association or a new aspect of a known association between a medicine and an event. Specialists review clinical details, timing, biological plausibility, alternative causes, reporting patterns, and available research. Statistical methods can help find events reported more frequently than expected, but a numerical signal does not prove causation. Further investigation can include targeted studies, database analyses, laboratory work, or requests for additional information.

What Actions Can Result From Pharmacovigilance?

Safety findings can lead to updated warnings, revised dosing instructions, new monitoring recommendations, restricted use, additional studies, or risk-management measures. Regulators and manufacturers can communicate new information to healthcare professionals and patients. A product can be suspended or withdrawn when risks outweigh benefits and cannot be managed adequately. Some signals are closed without regulatory action when the evidence does not support a causal association.

What Are the Limitations of Pharmacovigilance?

Spontaneous reports can be incomplete, duplicated, delayed, or influenced by publicity and reporting habits. The number of reports cannot usually show how frequently an event occurs because the total number of exposed patients is often unknown. Underreporting can hide uncommon risks, while underlying disease and other medicines can complicate causality assessment. Pharmacovigilance therefore combines several data sources rather than relying on one reporting system alone.

Frequently Asked Questions About Pharmacovigilance

Is an adverse-event report proof that a medicine caused harm?

No. A report documents that an event occurred after or during medicine use, but it does not establish causation by itself. Clinical review and additional evidence are needed.

Who can report a suspected medicine side effect?

Patients, caregivers, healthcare professionals, and manufacturers can report suspected adverse events through the applicable national reporting system. Reports are useful even when the relationship to the medicine is uncertain.

What is a pharmacovigilance safety signal?

It is information suggesting a possible new risk or a new feature of a known risk that deserves investigation. A signal is a reason to evaluate evidence, not a confirmed conclusion.

Does pharmacovigilance continue after drug approval?

Yes. Postmarketing monitoring is necessary because rare, delayed, or population-specific risks might not be fully identified before approval.

References

Pharmacovigilance. World Health Organization. https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance. Date Accessed August 6, 2026.

Best Practices for FDA Staff in the Postmarketing Safety Surveillance of Human Drug and Biological Products. U.S. Food and Drug Administration. https://www.fda.gov/media/130216/download. Date Accessed August 6, 2026.

Signal Management. European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/signal-management. Date Accessed August 6, 2026.

FDA Adverse Event Monitoring System (AEMS). U.S. Food and Drug Administration. https://www.fda.gov/drugs/surveillance-post-drug-approval-activities/fda-adverse-event-monitoring-system-aems. Date Accessed August 6, 2026.

Under-reporting of adverse drug reactions: a systematic review. PubMed. https://pubmed.ncbi.nlm.nih.gov/16689555/. Date Accessed August 6, 2026.